Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DUAVEE vs NOLVADEX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
DUAVEE is a combination of conjugated estrogens (CE) and bazedoxifene (BZA). CE activates estrogen receptors (ERα and ERβ) to relieve menopausal symptoms; BZA is a selective estrogen receptor modulator (SERM) that antagonizes ER in the endometrium to prevent endometrial hyperplasia.
NOLVADEX (tamoxifen citrate) is a nonsteroidal selective estrogen receptor modulator (SERM) that competitively inhibits estrogen binding to estrogen receptors in breast tissue, thereby blocking estrogen-mediated cell proliferation. It also has partial agonist activity in other tissues such as bone and endometrium.
Moderate to severe vasomotor symptoms due to menopause,Prevention of postmenopausal osteoporosis
Treatment of metastatic breast cancer in women and men,Adjuvant treatment of breast cancer in women with node-positive or node-negative disease following primary surgery,Reduction of breast cancer incidence in high-risk women (pre- and postmenopausal) for primary prevention,Reduction of contralateral breast cancer risk in women with ductal carcinoma in situ (DCIS) or prior breast cancer,Off-label: Induction of ovulation in anovulatory infertility; treatment of gynecomastia; reduction of breast cancer risk in BRCA mutation carriers
One tablet (conjugated estrogens 0.45 mg/bazedoxifene 20 mg) orally once daily.
20-40 mg orally once daily; for breast cancer, 20 mg/day. For adjuvant therapy, 20 mg/day for 5 years. For ductal carcinoma in situ, 20 mg/day for 5 years. For reduction of breast cancer incidence in high-risk women, 20 mg/day for 5 years.
Conjugated estrogens: terminal half-life of estrone sulfate is approximately 10-24 hours. Bazedoxifene: terminal half-life is approximately 30 hours. Clinically, steady state is achieved within 7 days for estrogens and 10-14 days for bazedoxifene.
Tamoxifen: 5-7 days (terminal). N-desmethyltamoxifen (active metabolite): 14 days. Steady-state achieved in 3-4 weeks.
Conjugated estrogens are primarily metabolized in the liver via phase II conjugation (sulfation and glucuronidation) by enzymes such as UGT1A1, UGT1A8, UGT1A9, UGT2B7, and SULT1A1. Bazedoxifene undergoes hepatic metabolism via glucuronidation by UGT1A1, UGT1A8, UGT1A9, and UGT2B7, with minimal CYP involvement.
Extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2D6 (to active metabolite endoxifen) and CYP3A4, with contributions from CYP2B6, CYP2C9, and CYP2C19. Undergoes glucuronidation and sulfation. Endoxifen is further metabolized by CYP3A4.
Conjugated estrogens are primarily excreted in urine as glucuronide and sulfate conjugates, with approximately 10-15% excreted in feces via biliary elimination. Bazedoxifene is mainly eliminated in feces (85%) with minimal renal excretion (<1% as unchanged drug).
Primarily fecal (65%) as conjugates; renal excretion accounts for approximately 25% as metabolites and <0.5% as unchanged drug. Biliary elimination contributes 10%.
Conjugated estrogens: extensive binding to albumin (approximately 80-85%). Bazedoxifene: highly bound (>99%) to albumin and alpha-1-acid glycoprotein.
>99% bound primarily to albumin.
Conjugated estrogens: Vd approximately 0.5-2 L/kg, indicating distribution into total body water and tissues. Bazedoxifene: Vd approximately 1.2 L/kg, suggesting extensive tissue distribution.
50-60 L/kg, indicating extensive tissue distribution (e.g., breast, liver, uterus).
Conjugated estrogens: oral bioavailability is approximately 30-50% due to first-pass metabolism. Bazedoxifene: absolute oral bioavailability is approximately 6% due to extensive first-pass glucuronidation.
Oral: Approximately 100% after first pass due to extensive hepatic metabolism; absolute bioavailability is nearly complete but variable.
No dosage adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl <30 m L/min), use with caution; no specific guidelines, consider reduced dose.
Contraindicated in Child-Pugh Class C (severe hepatic impairment). Use with caution in Child-Pugh Class A or B; no specific dose adjustment established, but monitor closely.
Contraindicated in Child-Pugh class C. For Child-Pugh class B, reduce dose by 50% (e.g., 20 mg every other day). For Child-Pugh class A, no adjustment needed.
Not indicated for use in pediatric patients. Safety and efficacy have not been established.
Safety and efficacy not established in pediatric patients for FDA-approved indications. Off-label use for gonadotropin-independent precocious puberty: 20 mg orally once daily (monitor for potential risks).
No specific dose adjustment recommended. Higher risk of adverse events (e.g., thromboembolism, stroke) in women >65 years of age; use lowest effective dose for shortest duration.
No specific dose adjustment recommended based on age alone; dosing same as adults. Monitor for increased risk of thromboembolic events, endometrial cancer, and cataracts. Start at lower end of dosing range (20 mg/day) if frail or with comorbidities.
Estrogen therapy increases the risk of endometrial cancer in women with a uterus. Concomitant use of a progestin or bazedoxifene is required to reduce this risk. Cardiovascular disorders: Estrogen-alone therapy may increase risk of stroke and DVT. Estrogen plus progestin therapy increases risk of MI, stroke, invasive breast cancer, pulmonary emboli, and DVT. DUAVEE is not approved for cardiovascular disease prevention. Breast cancer: Estrogen plus progestin therapy increases risk of invasive breast cancer. Probable dementia: Estrogen plus progestin therapy increases risk in women 65+.
WARNING: SERIOUS AND LIFE-THREATENING EVENTS - NOLVADEX has been associated with an increased risk of uterine malignancies (including endometrial cancer and uterine sarcoma), stroke, and pulmonary embolism. These risks increase with duration of therapy and patient age. Use only when benefit outweighs risk. Educate patients about symptoms of these events and seek prompt medical attention.
Cardiovascular disorders (stroke, DVT, MI, pulmonary embolism),Malignant neoplasms (endometrial cancer, breast cancer),Gallbladder disease,Hypertriglyceridemia,Fluid retention,Hypocalcemia,Hereditary angioedema,Exacerbation of endometriosis,Exacerbation of asthma, diabetes, migraine, porphyria, SLE, hepatic hemangiomas,Retinal vascular thrombosis
Increased risk of endometrial cancer, uterine sarcoma, and other uterine malignancies; perform baseline gynecologic exam and monitor for abnormal bleeding,Increased risk of thromboembolic events (DVT, PE, stroke); avoid in patients with history of thromboembolism,Hepatotoxicity: elevated liver enzymes, hepatitis, and hepatic steatosis; monitor periodic liver function tests,Ocular effects: cataracts, retinopathy; perform periodic eye exams,Hypercalcemia: may occur in patients with bone metastases; monitor serum calcium,Bone density loss: may cause decreased bone mineral density in premenopausal women; consider calcium and vitamin D supplementation,QT prolongation: use caution with other QT-prolonging drugs or electrolyte imbalances,Fetal harm: can cause fetal harm if used during pregnancy; advise women of childbearing age to use effective contraception
Undiagnosed abnormal genital bleeding,Known, suspected, or history of breast cancer,Known or suspected estrogen-dependent neoplasia,Active or past history of venous thromboembolism (VTE),Active or past history of arterial thromboembolism (e.g., stroke, MI),Known protein C, protein S, or antithrombin deficiency or other thrombophilic disorders,Hypersensitivity to any component,Pregnancy
History of deep vein thrombosis (DVT) or pulmonary embolism (PE),History of cerebral vascular accident (CVA) or transient ischemic attack (TIA),Known hypersensitivity to tamoxifen or any component of the formulation,Pregnancy (avoid use unless potential benefit justifies potential risk to fetus); use in women of childbearing age only with adequate contraception,Concurrent use with warfarin or other coumarin-type anticoagulants (relative contraindication due to increased bleeding risk),Severe hepatic impairment (Child-Pugh class C)
Grapefruit juice may increase estrogen levels; avoid large amounts. No other significant food interactions. Alcohol may increase risk of liver issues; limit intake.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4, potentially altering tamoxifen metabolism. Avoid St. John's wort. No other specific dietary restrictions, but maintain a balanced diet. Alcohol should be limited due to increased risk of liver enzyme elevation.
DUAVEE (conjugated estrogens/bazedoxifene) is contraindicated in pregnancy. Estrogens may cause fetal harm; first trimester exposure is associated with congenital anomalies including cardiovascular and limb defects. Second and third trimester exposure increases risk of urogenital abnormalities and delayed cognitive development. Bazedoxifene is a selective estrogen receptor modulator; animal studies show embryotoxicity and fetotoxicity at clinically relevant doses.
Nolvadex (tamoxifen) is classified as FDA Pregnancy Category D. There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience. First trimester exposure is associated with spontaneous abortions, birth defects (including craniofacial, genital, and skeletal anomalies), and fetal death. Second and third trimester exposure may cause fetal harm including pulmonary hypoplasia and growth retardation. Use is contraindicated during pregnancy.
Contraindicated during breastfeeding. Estrogens and bazedoxifene are excreted in human milk; M/P ratio not reported. Estrogens may reduce milk production and quality. Potential for adverse effects in nursing infants.
Tamoxifen is excreted in human milk. The milk-to-plasma ratio (M/P) is approximately 0.5-0.75. Due to potential serious adverse reactions in nursing infants, including hormonal effects and carcinogenicity, breastfeeding is not recommended during tamoxifen therapy and for at least 3 months after the last dose.
No dose adjustments applicable; do not use in pregnancy. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) are irrelevant due to contraindication.
Tamoxifen is contraindicated in pregnancy; therefore, dose adjustments are not applicable. If pregnancy occurs during therapy, discontinue tamoxifen immediately and manage with alternative therapies. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered hepatic metabolism) may reduce tamoxifen exposure, but no dose adjustments have been studied or recommended due to risk.
DUAVEE (conjugated estrogens/bazedoxifene) is indicated for moderate-to-severe vasomotor symptoms and osteoporosis prevention in postmenopausal women with a uterus. Avoid in women with intact uterus who are not on a progestin; bazedoxifene is the progestin component. Contraindicated in women with undiagnosed abnormal genital bleeding, known/suspected pregnancy, breast cancer, estrogen-dependent neoplasia, active DVT/PE, or history of these conditions. Monitor for thromboembolic events. Not for use in women with prior hysterectomy. Discontinue if jaundice or visual disturbances occur.
NOLVADEX (tamoxifen) is a selective estrogen receptor modulator (SERM) indicated for the treatment and prevention of breast cancer. Monitor for endometrial hyperplasia and thromboembolic events. Use with caution in patients with history of DVT/PE. CYP2D6 inhibitors (e.g., paroxetine) reduce conversion to active metabolite endoxifen; avoid coadministration. Tamoxifen can cause tumor flare in bone metastases. Discontinue 2-3 months before attempting pregnancy due to long half-life. Regular gynecologic exams and ophthalmologic monitoring recommended.
Take DUAVEE once daily with or without food.,This medication is for postmenopausal women with a uterus; it contains both estrogen and a progestin-like drug to protect the uterine lining.,Do not use if you have any unexplained vaginal bleeding, are pregnant, have or have had breast cancer, blood clots, or liver disease.,Report promptly any signs of blood clots (leg pain/swelling, chest pain, sudden shortness of breath) or stroke (sudden headache, vision/speech changes).,DUAVEE may increase risk of gallbladder disease, dementia (if started after age 65), and endometrial hyperplasia if the progestin component fails.,Smoking while on DUAVEE increases risk of blood clots; avoid smoking.,DUAVEE does not prevent heart attack or stroke; in fact, it may increase cardiovascular risk, especially in older women.,Store at room temperature, away from moisture and heat.,If you miss a dose, take it as soon as possible; if almost time for the next dose, skip the missed dose and resume regular schedule. Do not double dose.,You will need regular medical check-ups including mammograms and pelvic exams.
Take exactly as prescribed; do not skip doses.,Report any unusual vaginal bleeding, pelvic pain, or changes in vision immediately.,Avoid grapefruit juice as it may affect drug levels.,Use effective non-hormonal contraception during therapy and for 2 months after stopping.,Do not take St. John's wort or other herbal supplements without consulting your doctor.,Report leg swelling, chest pain, or shortness of breath promptly.,May cause hot flashes, nausea, or fatigue; these are not reasons to stop without consulting your doctor.,Attend all scheduled gynecologic and eye exams.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DUAVEE vs NOLVADEX, answered by our medical review team.
DUAVEE is a Selective Estrogen Receptor Modulator/Estrogen Combination that works by DUAVEE is a combination of conjugated estrogens (CE) and bazedoxifene (BZA). CE activates estrogen receptors (ERα and ERβ) to relieve menopausal symptoms; BZA is a selective estrogen receptor modulator (SERM) that antagonizes ER in the endometrium to prevent endometrial hyperplasia.. NOLVADEX is a Selective Estrogen Receptor Modulator that works by NOLVADEX (tamoxifen citrate) is a nonsteroidal selective estrogen receptor modulator (SERM) that competitively inhibits estrogen binding to estrogen receptors in breast tissue, thereby blocking estrogen-mediated cell proliferation. It also has partial agonist activity in other tissues such as bone and endometrium.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DUAVEE and NOLVADEX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DUAVEE is: One tablet (conjugated estrogens 0.45 mg/bazedoxifene 20 mg) orally once daily.. The standard adult dose of NOLVADEX is: 20-40 mg orally once daily; for breast cancer, 20 mg/day. For adjuvant therapy, 20 mg/day for 5 years. For ductal carcinoma in situ, 20 mg/day for 5 years. For reduction of breast cancer incidence in high-risk women, 20 mg/day for 5 years.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DUAVEE and NOLVADEX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DUAVEE is classified as Category C. DUAVEE (conjugated estrogens/bazedoxifene) is contraindicated in pregnancy. Estrogens may cause fetal harm; first trimester exposure is associated with congenital anomalies includi. NOLVADEX is classified as Category C. Nolvadex (tamoxifen) is classified as FDA Pregnancy Category D. There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing expe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.